Pulmatrix, Inc. PULM PHARMA

Q: What is the current share price of Pulmatrix, Inc. (PULM)?

As of 2026-09-19 21:16 PDT, Pulmatrix, Inc. (PULM) trades at $1.40 on NasdaqCM. Its 52-week range is $1.19 to $5.19.

Q: What is the market capitalisation of PULM?

Pulmatrix, Inc. (PULM) has a market capitalisation of $5.11M on NasdaqCM.

Q: What is the P/E ratio of PULM?

PULM trades at a trailing price-to-earnings (P/E) ratio of -1.27. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.30.

Q: What is the return on equity (ROE) of PULM?

PULM has a return on equity (ROE) of -98.35%. Its return on capital employed (ROCE) is -135.67%.

Q: Is PULM a good stock to buy?

This page provides a data-driven analysis of Pulmatrix, Inc. (PULM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.pulmatrix.com

Company Profile ↓

$1.40

-70.00% 1Y

Mkt Cap$5.11M

P/E-1.27

P/B3.30

52W High$5.19

52W Low$1.19

Book Value$0.44

EPS (TTM)$-1.10

Company Overview

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.00.

Recent Developments

Trailing 12 Months Year-on-year growth — revenue -100.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-
1 Year:	-100.00%

Stock Price Performance

1 Year:	-70.00%
6 Months:	-31.95%
3 Months:	-1.76%
1 Month:	-15.96%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 5% of range

$1.19 $5.19

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)37.30 · Neutral

Price Performance

1M-15.96%

3M-1.76%

6M-31.95%

1Y-70.00%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Trading 73.1% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-1.27

Industry PE

24.83

Forward P/E

-0.31

PEG Ratio

Book Value

$0.44

Price to Book

3.30

P/S

EV/EBITDA

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

Revenue (YoY)

-100.00%

Earnings (YoY)

Profitability & Returns

ROCE

-135.67%

ROE

-98.35%

ROA

-54.69%

Profit Margin

0.00%

Op Margin

0.00%

Gross Margin

0.00%

EPS (Latest Qtr)

$-0.32

EPS (TTM)

$-1.10

Balance Sheet & Liquidity

Debt/Equity

0.00

Quick Ratio

3.15

Current Ratio

4.70

Debt

Total Assets

$4.50M

Current Assets

$4.49M

Working Capital

$3.80M

Ownership

Promoter Holding

0.78%

Chg in Prom Hold

0.01%

FII / Inst Holding

9.16%

Chg in FII Hold

0.10%

Financial Snapshot

Enterprise Value

$5.11M

Total Revenue (TTM)

EBITDA

$-5.17M

Free Cash Flow

$-3.17M

Operating Cash Flow

$-3.91M

Shares Outstanding

3.65M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PULM Pulmatrix, Inc. PHARMA	1.40	-1.27	$5.11M	0.00%	-135.67%	-98.35%	-	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2014	Sep 2014	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.82M	1.41M	2.76M	3.50M	4.37M	1.39M	2.25M	1.07M	1.16M	1.33M	1.87M	1.50M	1.84M	1.75M	5.88M	1.55M	366.00K	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.85M	1.55M	866.00K	908.00K	1.29M
Operating Income	-2.45M	-2.59M	-1.72M	-2.75M	-11.32M	-4.66M	-5.44M	-8.97M	-3.00M	-3.31M	-5.43M	-4.30M	-5.11M	-6.13M	-4.83M	-5.11M	-4.96M	-7.95M	-3.68M	-4.74M	-1.17M	-1.28M	-4.08M	-3.85M	-8.19M	-4.96M	-4.56M	-5.10M	-4.58M	-3.99M	-3.94M	747.00K	-5.90M	-2.66M	-	-1.85M	-1.55M	-866.00K	-908.00K	-1.29M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.85M	-1.55M	-866.00K	-908.00K	-1.29M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.81M	-1.55M	-877.00K	-928.00K	-1.17M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-6.94M	-11.13M	-1.71M	-1.80M	-14.90M	-4.93M	-5.67M	-9.19M	-3.16M	-3.48M	-5.60M	-4.45M	-5.22M	-6.19M	-4.82M	-5.22M	-5.16M	-7.84M	-3.56M	-4.69M	-1.17M	-10.55M	-4.10M	-3.85M	-8.18M	-4.97M	-4.59M	-5.05M	-4.45M	-3.82M	-3.77M	825.00K	-5.81M	-2.59M	-	-1.81M	-1.55M	-877.00K	-928.00K	-1.17M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.36	-1.45	-1.22	-1.04	-1.03	0.23	-1.59	-0.71	-	-0.50	-0.42	-0.24	-	-0.32
R&D Expense	1.73M	1.93M	619.00K	918.00K	1.61M	2.19M	3.43M	2.44M	1.51M	1.67M	3.36M	2.62M	3.22M	4.01M	3.06M	3.22M	2.18M	3.16M	3.30M	5.29M	3.18M	3.87M	3.86M	4.54M	4.03M	4.15M	4.34M	5.29M	3.87M	4.17M	3.96M	3.51M	2.83M	814.00K	-	19.00K	14.00K	8.00K	-	3.00K

Profit & Loss (Annual)

Figures in USD.

Metric	Mar 2014	Dec 2014	Mar 2015	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	0	352.00K	0	1.20M	835.00K	335.00K	153.00K	7.91M	12.63M	-	6.07M	7.30M	7.81M	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	25.02M	22.04M	14.95M	5.17M
Operating Income	-3.12M	-9.08M	-6.71M	-23.02M	-24.87M	-17.48M	-20.40M	-20.69M	-9.86M	-	-18.95M	-14.74M	-7.14M	-5.17M
EBITDA	-	-	-	-	-	-	-	-	-	-	-17.40M	-13.27M	-6.71M	-5.17M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-18.84M	-14.12M	-9.56M	-5.16M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-3.12M	-24.14M	-6.69M	-26.17M	-27.84M	-18.06M	-20.56M	-20.60M	-19.31M	-	-18.84M	-14.12M	-9.56M	-5.16M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-5.46	-3.87	-2.62	-1.41
R&D Expense	1.38M	6.59M	2.18M	7.19M	10.15M	10.24M	12.97M	12.85M	15.61M	15.38M	18.24M	15.52M	7.17M	38.00K

Balance Sheet (Annual)

Figures in USD.

Metric	Mar 2013	Dec 2013	Mar 2014	Dec 2014	Mar 2015	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	15.58M	1.55M	10.68M	44.87M	16.66M	15.98M	14.72M	36.10M	38.09M	-	40.95M	33.96M	9.94M	4.14M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	38.15M	20.84M	9.92M	4.13M
Cash & Equivalents	-	1.43M	-	451.00K	-	18.90M	4.18M	3.55M	2.56M	23.44M	31.66M	-	35.63M	19.17M	9.52M	4.09M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	67.00K	1.30M	928.00K	0	-
Total Liabilities	-	-	-	44.77M	-	12.27M	7.90M	5.84M	2.88M	25.08M	14.96M	-	9.84M	15.96M	996.00K	329.00K
Current Liabilities	-	-	947.00K	43.46M	635.00K	3.60M	4.65M	5.84M	2.88M	17.20M	8.18M	-	5.02M	3.91M	929.00K	329.00K
Long Term Debt	-	-	-	-	-	5.69M	3.22M	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	2.29M	857.00K	8.76M	0	-
Total Equity	47.00K	-74.84M	14.63M	-78.79M	10.04M	32.61M	8.76M	10.14M	11.84M	11.02M	23.14M	-	31.11M	18.00M	8.95M	3.81M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	3.64M	3.65M	3.65M	3.65M

Cash Flows (Annual)

Figures in USD.

Metric	Mar 2014	Dec 2014	Mar 2015	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-	-14.48M	-16.76M	3.23M	-12.48M	-	-19.36M	-15.98M	-10.72M	-5.43M
Investing Cash Flow	-	-	-	-	-	-74.00K	-19.00K	-58.00K	-281.00K	-	-86.00K	-676.00K	-398.00K	0
Financing Cash Flow	-	-	-	-	-	13.92M	15.79M	17.70M	20.98M	43.48M	1.23M	53.00K	0	-
Capital Expenditure	-0	-285.00K	-156.00K	-266.00K	-455.00K	-74.00K	-19.00K	-58.00K	-281.00K	-144.00K	-86.00K	-676.00K	-398.00K	-
Free Cash Flow	-	-	-	-	-	-14.55M	-16.78M	3.17M	-12.76M	-	-19.44M	-16.66M	-11.11M	-5.43M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-18.21M	-16.61M	-11.11M	-5.43M

Ratios (Annual)

Figures in %.

Metric	Mar 2014	Dec 2014	Mar 2015	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-2,578.4%	-	-1,916.6%	-2,978.0%	-5,216.4%	-13,333.3%	-261.6%	-78.1%	-	-312.1%	-202.0%	-91.5%	-
Net Margin %	-	-6,859.1%	-	-2,178.8%	-3,334.5%	-5,389.9%	-13,439.9%	-260.4%	-152.8%	-	-310.3%	-193.5%	-122.5%	-
ROE %	-21.3%	30.6%	-66.6%	-80.3%	-317.8%	-178.1%	-173.6%	-186.9%	-83.4%	-	-60.5%	-78.5%	-106.8%	-135.5%
ROCE %	-21.3%	21.7%	-66.8%	-55.8%	-207.0%	-172.4%	-172.2%	-109.5%	-33.0%	-	-52.7%	-49.1%	-79.3%	-135.7%

Shareholding Pattern

Insiders

0.78%

Institutions

9.16%

Public Float

9.23%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Renaissance Technologies, LLC	3.36%	122.70K	$176.69K
2	Blackrock Inc.	1.50%	54.90K	$79.05K
3	Geode Capital Management, LLC	0.91%	33.30K	$47.95K
4	Vanguard Capital Management LLC	0.88%	32.29K	$46.50K
5	SBI Securities Co., Ltd.	0.86%	31.29K	$45.05K
6	Shay Capital LLC	0.52%	18.86K	$27.15K
7	Vanguard Fiduciary Trust Co	0.40%	14.71K	$21.19K
8	State Street Corporation	0.38%	13.95K	$20.08K
9	Xtx Topco Ltd	0.33%	11.99K	$17.27K
10	UBS Group AG	0.01%	515	$741

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PULM

Google News ue, 21 Apr 2026

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger - PR Newswire

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOMjUzb01IZUJjRlhfd2RzTlVTaURJMkIzeFpXdWl4OGs4VDFlOTZDZXUtXzc5dVJSbXlTNFFmUVZhNlduQm1POTNTTk1Mb3ZFU0t4QWlBQzZpYmI5b3dubHZWQkNVUW04cjlTQkVDUnhabWVlLUtWNWpoMmlsaUg0UXA4NVg1UkppNWljbH…

Google News Fri, 04 Sep 2026

Pulmatrix Inc (NASDAQ: PULM) Share Price, PULM Stock News, PULM Share Price & Updates - kalkine.com.au

<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE8tM20xS3hSNE43XzM5UW9MV2FBdjUyQ3ZQLVc2Mm1KTUpuYW1yTnlCZ0NsZm9XWGctWHBPajJiN3ktZkUwQ29FVzV2c1BSdV8zS1p5dWRn?oc=5" target="_blank">Pulmatrix Inc (NASDAQ: PULM) Share Price, PULM Stoc…

Google News Mon, 13 Apr 2026

PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire

<a href="https://news.google.com/rss/articles/CBMiiAJBVV95cUxOY3N0NUhfT1lfUzhraXlIb1NnUUpCVHZIdndabXQ3OTlqTklJVTZHcUdkLUVVRk45dUR4YnRGUG1GVTdVR3pyWDNxbEJuMG13dmxzVmtjQ096aVI1SXRMOUNjbVVUYkw1U0c0R1BjM0RSREYyd0lVUjN3djF4b2pVcGFHd1dDY1hKalVHYW…

Google News Sat, 08 Aug 2026

Pulmatrix (PULM) Holds at $1.66 as Trading Range Between $1.58 and $1.74 Defines Action - Last Point Support - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOUjE0WDYtbWY5SWRYM2VkQndabGNFbW1UUjJWMEdCR3JmZEUyUkZrczB0dUhNUlFWTkJwc21MeG1qRVRQazEwdVhyRF9EM3JadXRfT0Z0WHFwdmQwZUEzUFp0ZUpzNnR4VTJEZ0JVOWhoSXpzX1pYSlVLbzVsTjB6S0F2S3Bzb3g2M1F4MH…

Google News Sun, 26 Jul 2026

Pulmatrix Inc (PULM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5sVlBJeVFFcjlwTjJ2bDNBV1B2QTFPNjBIZlQxa1FiWUtrVGx1TmRJV2xlbm9wYkxHbzFnZmVpVDFXZUJ0TjN1WkxzemxtMjBISVhfTWs3MmhQZmdva0p4S1hkdnZHZm8?oc=5" target="_blank">Pulmatrix Inc (PULM) Shareho…

Google News Mon, 15 Jun 2026

PULM Q2 2025 Earnings: Net Loss Reported, Stock Rises as Investors Look Past Revenue Absence - Share Repurchase Impact - po-news-eg.net

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxORlBJOWstd2tNRjBsQ2E2eElab0NhTWR5MExvX3luYXYwVmhmNW5OaldkSE9WUUpGUDN2S2J2TXBoaXI4Qk5oV1JNdnMyYzV3SE5ULXhUY092eTdjX1FoZXNLSDQwY3Z4N2xIb3EtWnFvTkxwUGVqeFJGbjRJVTNtbFZ3dHFfd1lHOFhCYz…

PULM — Frequently Asked Questions

What is the current share price of Pulmatrix, Inc. (PULM)?

As of 2026-09-19 21:16 PDT, Pulmatrix, Inc. (PULM) trades at $1.40 on NasdaqCM. Its 52-week range is $1.19 to $5.19.

What is the market capitalisation of PULM?

Pulmatrix, Inc. (PULM) has a market capitalisation of $5.11M on NasdaqCM.

What is the P/E ratio of PULM?

PULM trades at a trailing price-to-earnings (P/E) ratio of -1.27. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.30.

What is the return on equity (ROE) of PULM?

PULM has a return on equity (ROE) of -98.35%. Its return on capital employed (ROCE) is -135.67%.

Is PULM a good stock to buy?

This page provides a data-driven analysis of Pulmatrix, Inc. (PULM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Pulmatrix, Inc. PULM PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger - PR Newswire

Pulmatrix Inc (NASDAQ: PULM) Share Price, PULM Stock News, PULM Share Price & Updates - kalkine.com.au

PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire

Pulmatrix (PULM) Holds at $1.66 as Trading Range Between $1.58 and $1.74 Defines Action - Last Point Support - vinanet.vn

Pulmatrix Inc (PULM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

PULM Q2 2025 Earnings: Net Loss Reported, Stock Rises as Investors Look Past Revenue Absence - Share Repurchase Impact - po-news-eg.net

PULM — Frequently Asked Questions

What is the current share price of Pulmatrix, Inc. (PULM)?

What is the market capitalisation of PULM?

What is the P/E ratio of PULM?

What is the return on equity (ROE) of PULM?

Is PULM a good stock to buy?

Explore More